Clinical Trials Logo

Clinical Trial Summary

Universal hearing screening at birth by use of otoacoustic emission (OAE) is now offered in most maternities in France to detect symptomatic hearing impairment at birth but screening of cCMV infection is not coupled with this screening. In this study, the feasibility of achieving before one month of age the diagnosis of congenital CMV diagnosis and as well as the confirmation of hearing loss in newborns who failed newborn hearing screening will be tested.


Clinical Trial Description

Congenital cytomegalovirus (cCMV) is the most frequent congenital infection in France. Around 90% of cCMV infected infants are asymptomatic at birth, of whom 7 to 20% develop sensorineural hearing loss (SNHL). cCMV explains at least 10% of all hearing loss cases in young children. Early antiviral treatment (implemented before 1 month of age) with ganciclovir or valganciclovir can improve hearing outcome. In the absence of universal screening, cCMV remains largely undetected because most infected neonates are asymptomatic or have non-specific symptoms. When symptoms become apparent or develop, it may be too late for confirmation that the infection is of congenital origin becausediagnosis of congenital infection is based on the detection of CMV in samples collected within 2 to 3 weeks after birth. The presence of CMV in samples collected after this time may represent postnatal infection which does not carry the risk of hearing loss or neurodevelopmental sequelae. Universal hearing screening at birth by use of otoacoustic emission (OAE) is now offered in most maternities in France to detect symptomatic hearing impairment at birth but screening of cCMV infection is not coupled with this screening. In this study, the feasibility of achieving before one month of age the diagnosis of congenital CMV diagnosis and as well as the confirmation of hearing loss in newborns who failed newborn hearing screening will be tested. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02139423
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date November 22, 2014
Completion date October 19, 2020

See also
  Status Clinical Trial Phase
Completed NCT01923636 - Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero N/A
Recruiting NCT03973359 - Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection Lombardy N/A
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Withdrawn NCT02594566 - Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine Phase 1
Completed NCT02351102 - Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Phase 2/Phase 3
Active, not recruiting NCT05170269 - Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) Phase 3
Not yet recruiting NCT06118515 - A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Phase 1
Completed NCT02782988 - Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
Completed NCT02645396 - A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
Terminated NCT01655212 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Phase 3
Completed NCT02710864 - A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
Completed NCT05754879 - Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular Risk
Terminated NCT03301415 - Asymptomatic Congenital CMV Treatment Phase 2
Completed NCT01376778 - A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Phase 3